Reflexion Pharmaceuticals

Reflexion Pharmaceuticals

Biotechnology, 201 Sansome St, San Francisco, California, 94104, United States, 1-10 Employees

reflexionpharma.com

  • twitter
  • LinkedIn

phone no Phone Number: +17*********

Who is REFLEXION PHARMACEUTICALS

Reflexion Pharmaceuticals is developing an entirely new class of molecules to overcome limitations of biologics. While protein-based drugs, especially monoclonal antibodies, have changed ...

Read More

map
  • 201 Sansome St, San Francisco, California, 94104, United States Headquarters: 201 Sansome St, San Francisco, California, 94104, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • Greg Went CEO:   Greg Went

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from REFLEXION PHARMACEUTICALS

Reflexion Pharmaceuticals Org Chart and Mapping

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Reflexion Pharmaceuticals

Answer: Reflexion Pharmaceuticals's headquarters are located at 201 Sansome St, San Francisco, California, 94104, United States

Answer: Reflexion Pharmaceuticals's phone number is +17*********

Answer: Reflexion Pharmaceuticals's official website is https://reflexionpharma.com

Answer: Reflexion Pharmaceuticals's revenue is Under $1 Million

Answer: Reflexion Pharmaceuticals's SIC: 2834

Answer: Reflexion Pharmaceuticals has 1-10 employees

Answer: Reflexion Pharmaceuticals is in Biotechnology

Answer: Reflexion Pharmaceuticals contact info: Phone number: +17********* Website: https://reflexionpharma.com

Answer: Reflexion Pharmaceuticals is developing an entirely new class of molecules to overcome limitations of biologics. While protein-based drugs, especially monoclonal antibodies, have changed the world, there remains significant unmet need due to the inherent properties of antibodies, including proteolytic instability, immunogenicity, and large size. Our therapies are designed to have comparable affinity and specificity to antibodies while being invisible to the human body. These attributes enable nearly complete proteolytic stability, greatly reduced immunogenicity, and reduced off-target toxicity. Due to their smaller size, our therapies may be delivered at a higher molar dose and may be able to penetrate tissues better than antibodies. We believe that Reflexions platform can generate therapies that are more efficacious and better tolerated than current biologics.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access